Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells.
By using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that efficiently cleave an mRNA sequence in vitro. In this study, a ribozyme variant was used to target the overlapping region of the mRNAs encoding human cytomegalovirus (HCMV) major transcription regulatory proteins IE1 and IE2. The variant is about 90 times more efficient in cleaving the IE1/IE2 mRNA sequence in vitro than the ribozyme derived from the wild type RNase P ribozyme. Our results provide the first direct evidence that a point mutation at nucleotide position 80 of RNase P catalytic RNA from Escherichia coli (U80--> C80) increases the rate of chemical cleavage, and another mutation at nucleotide position 188 (C188--> U188) enhances substrate binding of the ribozyme. Moreover, the variant is more effective in inhibiting viral IE1 and IE2 expression and growth in HCMV-infected cells than the wild type ribozyme. A reduction of about 99% in the expression level of IE1 and IE2 and a reduction of 10,000-fold in viral growth were observed in cells that expressed the variant. In contrast, a reduction of less than 10% in IE1/IE2 expression and viral growth was observed in cells that either did not express the ribozyme or produced a catalytically inactive ribozyme mutant. Thus, engineered RNase P ribozyme variants are highly effective in inhibiting HCMV gene expression and growth. These results also demonstrate the feasibility of engineering highly effective RNase P ribozymes for gene targeting applications, including anti-HCMV gene therapy.
Zou
Hua
H
Program in Infectious Diseases and Immunity, School of Public Health, University of California, Berkeley, California 94720, USA.
Lee
Jarone
J
Umamoto
Sean
S
Kilani
Ahmed F
AF
Kim
Joseph
J
Trang
Phong
P
Zhou
Tianhong
T
Liu
Fenyong
F
D000998:Antiviral Agents; D003587:Cytomegalovirus / Q000235:genetics* / Q000254:growth & development; D003586:Cytomegalovirus Infections / Q000628:therapy*; D015967:Gene Expression Regulation, Viral; D005818:Genetic Engineering; D015316:Genetic Therapy; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics; D016337:RNA, Catalytic / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D012367:RNA, Viral / Q000378:metabolism*; D012190:Retroviridae / Q000235:genetics; D043262:Ribonuclease P / Q000235:genetics* / Q000378:metabolism; D015534:Trans-Activators; D014764:Viral Proteins
D000998:Antiviral Agents; C088645:IE1 protein, cytomegalovirus; C069186:IE2 protein, Cytomegalovirus; D017874:Immediate-Early Proteins; D016337:RNA, Catalytic; D012333:RNA, Messenger; D012367:RNA, Viral; D015534:Trans-Activators; D014764:Viral Proteins; D043262:Ribonuclease P